| Literature DB >> 35089917 |
Roy Rillera Marzo1,2,3, Absar Ahmad4, Md Saiful Islam5,6, Mohammad Yasir Essar7, Petra Heidler8,9,10, Isabel King11,12, Arulmani Thiyagarajan13, Kittisak Jermsittiparsert14, Karnjana Songwathana15, Delan Ameen Younus16, Radwa Abdullah El-Abasiri17, Burcu Kucuk Bicer18, Nhat Tan Pham19,20, Titik Respati21, Susan Fitriyana22, Erwin Martinez Faller23, Aries Moralidad Baldonado24, Md Arif Billah25, Yadanar Aung26,27, Shehu Muhammad Hassan28, Muhammad Mujtaba Asad29, Kareem Ahmed El-Fass30, Sudip Bhattacharya31, Sunil Shrestha32, Nouran Ameen Elsayed Hamza33,34, Pascal Friedmann35, Michael Head36, Yulan Lin37, Siyan Yi38,39,40.
Abstract
BACKGROUND: Mass vaccination campaigns have significantly reduced the COVID-19 burden. However, vaccine hesitancy has posed significant global concerns. The purpose of this study was to determine the characteristics that influence perceptions of COVID-19 vaccine efficacy, acceptability, hesitancy and decision making to take vaccine among general adult populations in a variety of socioeconomic and cultural contexts.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35089917 PMCID: PMC8797205 DOI: 10.1371/journal.pntd.0010103
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Study sample characteristics according to residence country (n = 10,477).
| AU | AT | BD | EG | ID | IQ | MY | MM | NG | PH | TH | TR | VN | Other | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number | 156 | 1347 | 359 | 957 | 522 | 1021 | 1283 | 301 | 201 | 313 | 2365 | 827 | 651 | 174 | 10477 |
| Age | |||||||||||||||
| <30 years | 22(14.1) | 188(14.0) | 259(72.1) | 723(75.5) | 329(63.0) | 311(30.5) | 964(75.1) | 98(32.6) | 102(50.7) | 228(72.8) | 791(33.4) | 261(31.6) | 395(60.7) | 42(24.1) | 4713(45.0) |
| 31–45 years | 51(32.7) | 500(37.1) | 48(13.4) | 186(19.4) | 120(23.0) | 327(32.0) | 229(17.8) | 174(57.8) | 90(44.8) | 57(18.2) | 939(39.7) | 140(16.9) | 237(36.4) | 75(43.1) | 3173(30.3) |
| 46–60 years | 42(26.9) | 521(38.7) | 36(10.0) | 40(4.2) | 63(12.1) | 242(23.7) | 71(5.5) | 21(7.0) | 7(3.5) | 22(7.0) | 579(24.5) | 232(28.1) | 19(2.9) | 50(28.7) | 1945(18.6) |
| >60 years | 41(26.3) | 138(10.2) | 16(4.5) | 8(0.8) | 10(1.9) | 141(13.8) | 19(1.5) | 8(2.7) | 2(1.0) | 6(1.9) | 56(2.4) | 194(23.5) | 0(0.0) | 7(4.0) | 646(6.2) |
| Female | 92 (59.0) | 1106 (82.1) | 180 (50.1) | 598 (62.5) | 376 (72.0) | 530 (51.9) | 371 (28.9) | 176 (58.5) | 59 (29.4) | 247 (78.9) | 1288 (54.5) | 453 (54.8) | 340 (52.2) | 121 (69.5) | 5937 (56.7) |
| Urban resident | 94 (60.3) | 786 (58.4) | 213 (59.3) | 751 (78.5) | 310 (59.4) | 916 (89.7) | 1146 (89.3) | 269 (89.4) | 154 (76.6) | 166 (53.0) | 1602 (67.7) | 687 (83.1) | 199 (30.6) | 123 (70.7) | 7416 (70.8) |
| Education level | |||||||||||||||
| <Secondary | 58 (37.2) | 483 (35.9) | 33 (9.2) | 23 (2.4) | 278 (53.3) | 471 (46.1) | 67 (5.2) | 4 (1.3) | 8 (4.0) | 20 (6.4) | 492 (20.8) | 540 (65.3) | 105 (16.1) | 37 (21.3) | 2619 (25.0) |
| Secondary | 98 (62.8) | 169 (12.5) | 58 (16.2) | 500 (52.2) | 244 (46.7) | 424 (41.5) | 284 (22.1) | 42 (14.0) | 33 (16.4) | 0 | 705 (29.8) | 0 | 262 (40.2) | 51 (29.3) | 2870 (27.4) |
| >Secondary | 0 | 695 (51.6) | 268 (74.7) | 434 (45.4) | 0 | 126 (12.3) | 932 (72.6) | 255 (84.7) | 160 (79.6) | 293 (93.6) | 1168 (49.4) | 287 (34.7) | 284 (43.6) | 86 (49.4) | 4988 (47.6) |
| Currently employed | 134 (85.9) | 1239 (92.0) | 126 (35.1) | 682 (71.3) | 188 (36.0) | 566 (55.4) | 377 (29.4) | 261 (86.7) | 111 (55.2) | 126 (40.3) | 1924 (81.4) | 383 (46.3) | 433 (66.5) | 144 (82.8) | 6694 (63.9) |
| Ever married | 118 (75.6) | 1080 (80.2) | 154 (42.9) | 325 (34.0) | 269 (51.5) | 686 (67.2) | 328 (25.6) | 153 (50.8) | 95 (47.3) | 75 (24.0) | 1342 (56.7) | 511 (61.8) | 345 (53.0) | 124 (71.3) | 5605 (53.5) |
| Family economic status | |||||||||||||||
| Low | 27 (17.3) | 195 (14.5) | 92 (25.6) | 122 (12.7) | 286 (54.80 | 290 (28.4) | 366 (28.5) | 44 (14.6) | 26 (12.9) | 119 (38.0) | 1045 (44.2) | 247 (29.9) | 137 (21.0) | 20 (11.5) | 3016 (28.8) |
| Medium | 68 (43.6) | 761 (56.5) | 138 (38.4) | 337 (35.2) | 221 (42.3) | 557 (54.6) | 831 (64.8) | 75 (24.9) | 18 (9.0) | 193 (61.7) | 905 (38.3) | 413 (49.9) | 335 (51.5) | 81 (46.6) | 4933 (47.1) |
| High | 61 (39.1) | 391 (29.0) | 129 (35.9) | 498 (52.0) | 15 (2.9) | 174 (17.0) | 86 (6.7) | 182 (60.5) | 157 (78.1) | 1 (0.3) | 415 (17.5) | 167 (20.2) | 179 (27.5) | 73 (42.0) | 2528 (24.1) |
Values are the number (%) for categorical variables and mean (SD) for continuous variables. AU: Australia, AT: Austria, BD: Bangladesh, EG: Egypt, ID: Indonesia, IQ: Iraq, MY: Malaysia, MM: Myanmar, NG: Nigeria, PH: Philippines, TH: Thailand, TR: Turkey, VN: Vietnam. Other countries include Canada, China, Germany, India, Ireland, New Zeeland, Scotland, Sri-Lanka, and the United Kingdom.
Perceived effectiveness, acceptance, and drivers of COVID-19 vaccine uptake decision-making by country by socio-demographic characteristics (n = 10,477).
| Socio-demographic characteristics | Agreed that vaccines are effective to prevent and control COVID-19 | Would accept COVID-19 vaccines when available | Believed that convenience is important for people to decide whether to accept vaccines | Believed that health providers’ advice is important for people to decide whether to accept vaccines | Believed that cost of the vaccines is important for people to decide whether to accept vaccines | Expressed hesitancy to receive COVID-19 vaccines | |
|---|---|---|---|---|---|---|---|
| Age group | |||||||
| <30 years | 3975 (84.3) | 4114 (87.3) | 3858 (81.9) | 4196 (89.0) | 3195 (67.8) | 2372 (50.3) | |
| 31 to 45 | 2392 (75.4) | 2505 (78.9) | 2109 (66.5) | 2441 (76.9) | 1587 (50.0) | 1680 (52.1) | |
| 46 to 60 | 1372 (70.5) | 1430 (73.5) | 1230 (63.2) | 1399 (71.9) | 881 (45.3) | 1064 (54.7) | |
| 60+ | 514 (79.6) | 523 (81.0) | 479 (74.1) | 538 (83.3) | 313 (48.5) | 419 (64.9) | |
| P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | ||
| Female | 4482 (75.5) | 4682 (78.9) | 4151 (69.9) | 4727 (79.6) | 3175 (53.5) | 3112 (52.4) | |
| P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | P = 0.33 | ||
| Urban residence | 6022 (81.2) | 6300 (85.0) | 5733 (77.3) | 6271 (84.6) | 4492 (60.6) | 3840 (51.8) | |
| P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | ||
| Level of education | |||||||
| < Secondary | 1864 (71.2) | 1861 (71.1) | 1685 (64.3) | 1936 (73.9) | 1230 (47.0) | 1546 (59.0) | |
| Secondary | 2239 (78.0) | 2281 (79.5) | 2107 (73.4) | 2265 (78.9) | 1611 (56.1) | 1471 (51.3) | |
| > Secondary | 4150 (83.2) | 4430 (88.8) | 3884 (77.9) | 4373 (87.7) | 3135 (62.9) | 2518 (50.5) | |
| P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | ||
| Currently employed | 5064 (75.6) | 5346 (79.9) | 4593 (68.6) | 5226 (78.1) | 3388 (50.6) | 3607 (53.9) | |
| P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | P = 0.004 | ||
| Ever married | 4291 (76.6) | 4472 (79.8) | 3767 (67.2) | 4426 (79.0) | 2726 (48.6) | 3079 (54.9) | |
| P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | ||
| Family economic status | |||||||
| Low | 2285 (75.8) | 2360 (78.2) | 2242 (74.3) | 2436 (80.8) | 1924 (63.8) | 1624 (53.8) | |
| Medium | 3924 (79.5) | 4035 (81.8) | 3607 (73.1) | 4063 (82.4) | 2789 (56.5) | 2566 (52.0) | |
| High | 2044 (80.9) | 2177 (86.1) | 1827 (72.3) | 2075 (82.1) | 1263 (50.0) | 1345 (53.2) | |
| P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | P < 0.26 | ||
| Total | 8253 (78.8) | 8572 (81.8) | 7676 (73.3) | 8574 (81.8) | 5976 (57.0) | 5535 (52.8) | |
** Significant at P <0.01
Perceived COVID-19 vaccine effectiveness, acceptance, and determinants of the uptake decision-making by country (n = 10,477).
| Country | Agreed that vaccines are effective to prevent and control COVID-19,% (95%CI) | Would accept COVID-19 vaccines when available, % (95%CI) | Believed that convenience is important for people to decide whether to accept vaccines, % (95%CI) | Believed that health providers’ advice is important for people to decide whether to accept vaccines, % (95%CI) | Believed that cost of the vaccines is important for people to decide whether to accept vaccines, % (95%CI) | Expressed hesitancy to receive COVID-19 vaccines, % (95%CI) |
|---|---|---|---|---|---|---|
| Australia | 84.0 (78.0–90.0) | 64.7 (57.2–72.2) | 71.8 (64.7–78.9) | 78.8 (72.4–85.2) | 55.8 (48.0–63.5) | 53.2 (45.4–61.0) |
| Austria | 70.4 (67.9–72.8) | 71.0 (68.6–73.5) | 49.7 (47.0–52.3) | 66.1 (63.5–68.6) | 22.6 (20.4–24.9) | 65.3 (62.7–67.8) |
| Bangladesh | 83.0 (79.1–86.9) | 93.6 (91.0–96.1) | 90.8 (87.8–93.8) | 92.5 (89.7–95.2) | 73.3 (68.7–77.8) | 52.9 (47.8–58.1) |
| Egypt | 67.8 (64.9–70.8) | 80.8 (78.3–83.3) | 85.7 (83.5–87.9) | 87.0 (84.9–89.2) | 75.3 (72.6–78.1) | 31.5 (28.5–34.4) |
| Indonesia | 86.0 (83.0–89.0) | 68.6 (64.6–72.6) | 64.6 (60.4–68.7) | 93.5 (91.4–95.6) | 42.7 (38.5–47.0) | 68.6 (64.6–72.6) |
| Iraq | 84.4 (82.2–86.6) | 91.8 (90.1–93.5) | 79.5 (77.0–82.0) | 87.7 (85.6–89.7) | 36.0 (33.1–39.0) | 61.2 (58.2–64.2) |
| Malaysia | 95.9 (94.9–97.0) | 96.0 (95.0–97.1) | 95.7 (94.6–96.8) | 97.3 (96.5–98.2) | 91.3 (89.7–92.8) | 38.3 (35.6–41.0) |
| Myanmar | 85.0 (81.0–89.1) | 90.4 (87.0–93.7) | 86.7 (82.9–90.1) | 86.4 (82.5–90.2) | 70.4 (65.3–75.6) | 62.1 (56.6–67.6) |
| Nigeria | 85.1 (80.1–90.0) | 84.1 (79.0–89.1) | 88.6 (84.7–93.0) | 89.6 (85.3–93.8) | 79.6 (74.0–85.2) | 35.3 (28.7–41.9) |
| Philippines | 88.8 (85.3–92.3) | 81.5 (77.2–85.8) | 93.0 (90.1–95.8) | 93.9 (91.3–96.6) | 81.5 (77.2–85.8) | 34.2 (28.9–39.4) |
| Thailand | 68.6 (66.7–70.4) | 76.3 (74.6–78.0) | 65.5 (63.5–67.4) | 75.9 (74.2–77.6) | 58.5 (56.5–60.5) | 41.2 (39.2–43.2) |
| Turkey | 80.2 (77.4–82.9) | 81.3 (78.6–83.9) | 82.2 (79.6–84.8) | 79.7 (76.9–82.4) | 78.4 (75.5–81.2) | 74.7 (71.8–77.7) |
| Vietnam | 88.3 (85.9–90.8) | 89.9 (87.5–92.2) | 48.2 (44.4–52.1) | 69.3 (65.7–72.8) | 16.0 (13.2–18.8) | 86.0 (83.4–88.7) |
| Other | 69.0 (62.1–75.8) | 69.5 (62.7–76.4) | 57.5 (50.1–64.8) | 71.8 (65.2–78.5) | 43.1 (35.7–50.5) | 52.3 (44.9–59.7) |
Other countries include Canada, China, Germany, India, Ireland, New Zeeland, Scotland, Sri-Lanka, and the United Kingdom.
Factors related to perceived COVID-19 vaccine effectiveness, acceptance, and drivers of the uptake decision-making (n = 10477).
| Agreed that vaccines are effective to prevent and control COVID-19 | Would accept COVID-19 vaccines when available | Believed that convenience is important for people to decide whether to accept vaccines | Believed that healthcare providers’ advice is important for people to decide whether to accept vaccines | Believed that cost of the vaccines is important for people to decide whether to accept vaccines | Expressed hesitancy to receive COVID-19 vaccines | |
|---|---|---|---|---|---|---|
|
| ||||||
| Australia | 2.83 (1.64–4.88) | 1.16 (0.72–1.86) | 2.12 (1.32–3.38) | 2.05 (1.22–3.44) | 1.93 (1.23–3.03) | 1.01 (0.65–1.57) |
| Austria | 1.31 (0.92–1.85) | 1.30 (0.91–1.86) | 0.80 (0.58–1.11) | 0.81 (0.56–1.16) | 0.40 (0.28–0.56) | 1.78 (1.29–2.45) |
| Bangladesh | 1.67 (1.08–2.58) | 4.81 (2.78–8.31) | 5.52 (3.43–8.89) | 3.02 (1.78–5.11) | 2.64 (1.78–3.91) | 0.98 (0.68–1.42) |
| Egypt | 0.67 (0.47–0.96) | 1.34 (.92–1.95) | 3.27 (2.29–4.69) | 2.06 (1.39–3.05) | 3.37 (2.39–4.76) | 0.38 (0.27–0.53) |
| Indonesia | 3.58 (2.35–5.45) | 1.47 (0.99–2.17) | 1.26 (0.87–1.81) | 6.61 (4.04–10.83) | 0.65 (0.45–0.94) | 2.17 (1.51–3.11) |
| Iraq | 2.74 (1.88–3.99) | 6.65 (4.42–10.02) | 2.83 (2.00–4.00) | 3.19 (2.15–4.73) | 0.64 (0.46–0.90) | 1.48 (1.06–2.06) |
| Malaysia | 7.57 (4.88–11.74) | 7.62 (4.88–11.89) | 10.68 (7.04–16.19) | 8.99 (5.51–14.66) | 8.25 (5.69–11.97) | 0.52 (0.37–0.72) |
| Myanmar | 1.91 (1.20–3.02) | 2.67 (1.60–4.45) | 4.05 (2.57–6.38) | 1.82 (1.13–2.93) | 3.10 (2.08–4.63) | 1.32 (0.90–1.94) |
| Nigeria | 1.66 (0.99–2.78) | 1.37 (0.82–2.30) | 4.69 (2.74–8.01) | 2.21 (1.25–3.93) | 5.09 (3.19–8.13) | 0.44 (0.29–0.67) |
| Philippines | 3.11 (1.90–5.09) | 1.40 (0.89–2.21) | 6.77 (3.95–11.61) | 3.33 (1.85–5.98) | 3.35 (2.18–5.15) | 0.46 (0.32–0.69) |
| Thailand | 1.05 (0.75–1.48) | 1.62 (1.14–2.30) | 1.26 (0.92–1.74) | 1.31 (0.92–1.87) | 1.49 (1.08–2.05) | 0.58 (0.43–0.80) |
| Turkey | 2.16 (1.48–3.17) | 2.54 (1.72–3.75) | 3.45 (2.40–4.96) | 1.49 (1.00–2.20) | 4.58 (3.21–6.55) | 2.82 (1.99–3.98) |
| Vietnam | 3.33 (2.21–5.02) | 4.03 (2.64–6.17) | 0.60 (0.43–0.85) | 0.77 (0.52–1.13) | 0.19 (0.13–0.28) | 5.54 (3.80–8.07) |
| Other countries | R | R | R | R | R | R |
|
| ||||||
| <30 years | R | R | R | R | R | R |
| 31 to 45 years | 0.66 (0.57–0.76) | 0.58 (0.50–0.68) | 0.66 (0.57–0.75) | 0.54 (0.46–0.63) | 0.77 (0.68–0.88) | 0.93 (0.82–1.04) |
| 46 to 60 years | 0.61 (0.51–0.71) | 0.54 (0.45–0.64) | 0.66 (0.57–0.77) | 0.49 (0.41–0.59) | 0.71 (0.61–0.82) | 0.95 (0.82–1.09) |
| 60+ years | 0.82 (0.65–1.03) | 0.74 (0.57–0.94) | 0.85 (0.68–1.06) | 0.86 (0.66–1.11) | 0.62 (0.50–0.76) | 1.15 (0.94–1.40) |
|
| ||||||
| Female | R | R | R | R | R | R |
| Male | 1.28 (1.15–1.43) | 1.16 (1.03–1.30) | 1.09 (0.99–1.21) | 1.09 (0.97–1.22) | 0.99 (0.90–1.09) | 1.21 (1.11–1.32) |
|
| ||||||
| Rural | R | R | R | R | R | R |
| Urban | 1.35 (1.21–1.51) | 1.40 (1.25–1.57) | 1.25 (1.12–1.39) | 1.17 (1.04–1.32) | 1.05 (0.95–1.17) | 1.04 (0.95–1.15) |
|
| ||||||
| < Secondary | R | R | R | R | R | R |
| Secondary | 1.53 (1.33–1.76) | 1.42 (1.23–1.64) | 1.37 (1.20–1.56) | 1.08 (0.93–1.25) | 1.35 (1.19–1.54) | 1.12 (0.99–1.27) |
| > Secondary | 1.85 (1.61–2.13) | 2.68 (2.31–3.11) | 1.55 (1.36–1.77) | 2.31 (2.00–2.67) | 1.41 (1.23–1.61) | 1.18 (1.04–1.33) |
|
| ||||||
| Employed | R | R | R | R | R | R |
| Unemployed/student | 1.06 (0.92–1.21) | 0.96 (0.83–1.11) | 1.00 (0.88–1.14) | 1.23 (1.06–1.42) | 1.25 (1.10–1.40) | 0.81 (0.72–0.90) |
|
| ||||||
| Ever married | R | R | R | R | R | R |
| Never married | 0.92 (0.82–1.03) | 0.87 (0.77–0.99) | 1.14 (1.01–1.28) | 0.81 (0.72–0.93) | 1.05 (0.94–1.17) | 1.12 (1.01–1.24) |
|
| ||||||
| Low | R | R | R | R | R | R |
| Medium | 1.17 (1.04–1.32) | 1.12 (0.99–1.27) | 0.93 (0.83–1.05) | 1.18 (1.04–1.35) | 0.76 (0.68–0.85) | 0.82 (0.74–0.90) |
| High | 1.46 (1.25–1.70) | 1.48 (1.25–1.75) | 0.81 (0.70–0.94) | 1.09 (0.93–1.28) | 0.47 (0.41–0.54) | 0.90 (0.79–1.02) |
Other countries include Canada, China, Germany, India, Ireland, New Zealand, Scotland, Sri-Lanka, and the United Kingdom. Data were presents as adjusted odds ratio (confidence interval). R: Reference
*P<0.05
**P<0.01.